Sonoma Pharmaceuticals, Inc. (SNOA) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $2.24. It has a SharesGrow Score of 50/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Valuation: SNOA trades at a trailing Price-to-Earnings (P/E) of -1.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.01.
Financials: revenue is $14M, +4.4%/yr average growth. Net income is $3M (loss), growing at +11.1%/yr. Net profit margin is -24.2% (negative). Gross margin is 38.2% (+6.6 pp trend).
Balance sheet: total debt is $305,000 against $4M equity (Debt-to-Equity (D/E) ratio 0.07, conservative). Current ratio is 3.09 (strong liquidity). Debt-to-assets is 2.2%. Total assets: $14M.
Analyst outlook: 1 / 2 analysts rate SNOA as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 63/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 36/100 (Fail), Future 40/100 (Partial), Income 10/100 (Fail).
